Pharmacological Challenge Agents in Anxiety

Anxiety Disorders

Volumn , Issue , 2007, Pages 269-295

  Swain, J ^a   Koszycki, D ^a   Shlik, J ^b   Bradwejn, J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Doxapram; Norepinephrine; Panicogenic agent; Panicogens; Physiology

Indexed keywords

EID: 84952008080     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470986844.ch15     Document Type: Chapter

References (272)

1. Abelson, J.L., Glitz, D., Cameron, O.G. et al. (1992) Endocrine, cardiovascular and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry 32, 18-25.
2. Abelson, J.L., Weg, J.G., Nesse, R.M. & Curtis, G.C. (1996) Neuroendocrine responses to laboratory panic: cognitive intervention in doxapram model. Psychoneuroendocrinology 21, 375-90.
3. Albus, M., Zahn, P. & Breier, A. (1992) Anxiogenic properties of yohimbine. Eur Arch Psychiatry Clin Neurosci 241, 337-44.
4. Antony, M.M., Brown, T.A. & Barlow, D.H. (1997) Response to hyperventilation and 5.5% CO2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Am J Psychiatry 154, 1089-95.
5. Aronson, T.A., Carasiti, I., McBane, D. & Whitaker-Azmitia, P. (1989) Biological correlates of lactate sensitivity in panic disorder. Biol Psychiatry 26, 463-77.
6. Asmundson, G.J. & Stein, M.B. (1994) Triggering the false suffocation alarm in panic disorder patients by using a voluntary breath-holding procedure. Am J Psychiatry 151, 264-66.
7. Bailey, J.E., Argyropoulos, S., Kendrick, A., Nash, J., Lightman, S. & Nutt, D. (2001) Inhalation of 35% CO2 results in subjective fear and activates the HPA axis in healthy volunteers. J Psychopharmacol 15, A22.
8. Balon, R., Jordan, M., Pohl, R. & Yeragani, V.K. (1989) Family history of anxiety disorders in control subjects with lactate-induced panic attacks. Am J Psychiatry 14, 1304-6.
9. Balon, R., Petty, F., Yeragani, V.K., Kramer, G.L. & Pohl, R. (1993) Intravenous sodium lactate decreases plasma GABA levels in man. Psychopharmacology 110, 368-70.
10. Balon, R., Pohl, R., Yeragani, V.K., Rainey, J.M. Jr & Berchou, R. (1988) Follow-up study of control subjects with lactate-and isoproterenol-induced panic attacks. Am J Psychiatry 154, 238-41.
11. Balon, R., Yeragani, V.K., Pohl, R., Muench, J. & Berchou, R. (1990) Somatic and psychological symptoms during isoproterenol-induced panic attacks. Psychiatry Res 32, 103-12.
12. Bandelow, B., Wedekind, D., Pauls, J. et al. (2000) Salivary cortisol in panic attacks. Am J Psychiatry 157, 454-6.
13. Barnes, N.M. & Sharp, T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
14. Beck, J.G. & Berisford, M.A. (1992) The effects of caffeine on panic patients: response components of anxiety. Behavior Therapy 23, 405-22.
15. Bell, C.J., Forshall, S., Adrover, M. et al. (2002) Does 5-HT restrain panic? A tryphophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16, 5-14.
16. Bell, C.J. & Nutt, D.J. (1998) Serotonin and panic. Br J Psychiatry 172, 465-71.
17. Bellodi, L., Perna, G., Caldirola, D., Arancio, C., Bertani, A. & Di Bella, D. (1998) CO2-induced panic attacks: a twin study. Am J Psychiatry 155, 1184-88.
18. Benkelfat, C., Bradwejn, J., Meyer, E. et al. (1995) Functional neuroanatomy of CCK-4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152, 1180-4.
19. Ben-Zion, I.Z., Meiri, G., Greenberg, B.D., Murphy, D.L. & Benjamin, J. (1999) Enhancement of CO2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. Am J Psychiatry 156, 1635-7.
20. Bertani, A., Perna, G., Arancio, C., Caldirola, D. & Bellodi, L. (1997) Pharmacologic effect of imipramine, paroxetine, and sertraline in 35% carbon dioxide sensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 17, 97-101.
21. Biber, B. & Alkin, T. (1999) Panic disorder subtypes: differential responses to CO2 challenge. Am J Psychiatry 156, 739-44.
22. Bond, A.J., Feizollah, S. & Lader, M.H. (1995) The effects of d-fenfluramine on mood and performance, and on neuroendocrine indicators of 5-HT function. J Psychopharmacol 9, 1-8.
23. Bonn, J.A., Harrison, J. & Rees, W.L. (1971) Lactate-induced anxiety, therapeutic application. Br J Psychiatry 119, 468-71.
24. Boulenger, J.-P., Uhde, T.W., Wolff, A., III & Post, R.M. (1984) Increased sensitivity to caffeine in patients with panic disorders. Arch Gen Psychiatry 41, 1067-71.
25. Bradwejn, J. & Koszycki, D. (1991) Comparison of CO2-induced panic with cholecystokinin-induced panic in panic disorder. Prog Neuro-psychopharmacol Biol Psychiatry 15, 237-9.
26. Bradwejn, J. & Koszycki, D. (1994) Imipramine antagonism of panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151, 261-3.
27. Bradwejn, J., Koszycki, D., Annable, L., Couëtoux du Tertre, A., Reines, S. & Karkanias, C. (1992a) A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol Psychiatry 32, 903-12.
28. Bradwejn, J., Koszycki, D. & Bourin, M. (1991a) Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatr Neurosci 16, 91-5.
29. Bradwejn, J., Koszycki, D., Couetoux du Tertre, A. et al. (1994b) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51, 486-93.
30. Bradwejn, J., Koszycki, D., Cöuetoux du Tertre, A., Paradis, M. & Bourin, M. (1994a) Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Pychopharmacology 114, 257-61.
31. Bradwejn, J., Koszycki, D. & Meterissian, G. (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35, 83-5.
32. Bradwejn, J., Koszycki, D., Paradis, M., Reece, P., Hinton, J. & Sedman, A. (1995) Effect of CI-988 on cholecystokinin-tetrapeptide induced panic symptoms in healthy voluteers. Biol Psychiatry 38, 742-6.
33. Bradwejn, J., Koszycki, D., Payeur, R., Bourin, M. & Borthwick, H. (1992b) Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 149, 962-4.
34. Bradwejn, J., Koszycki, D. & Shriqui, C. (1991b) Enhanced sensitivity to cholecystokinin-tetrapeptide in PD. Arch Gen Psychiatry 48, 603-7.
35. Bradwejn, J., LeGrand, J.-M., Koszycki, D., Bates, J.H.T. & Bourin, M. (1998) Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 155, 280-2.
36. Brawman-Mintzer, O., Lydiard, R.B., Bradwejn, J. et al. (1997) Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 154, 700-2.
37. Broocks, A., Bandelow, B., George, A. et al. (2000) Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15, 153-61.
38. Bruce, M., Scott, N., Shine, P. & Lader, M. (1992) Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen Psychiatry 49, 867-9.
39. Buller, R., von Bardeleben, U., Maier, W. & Benkert, O. (1989) Specificity of lactate response in panic with concurrent depression and major depression. J Affect Disord 16, 109-113.
40. Bystritsky, A., Craske, M., Maidenberg, E., Vapnik, T. & Shapiro, D. (2000) Autonomic reactivity of panic patients during a CO2 inhalation procedure. Depress Anxiety 11, 15-26.
41. Caldirola, D., Perna, G., Arancio, C., Bertani, A. & Bellodi, L. (1997) The 35% CO2 challenge test in patients with social phobia. Psychiatry Res 71, 41-8.
42. Calverley, P.M.A., Robson, R.H., Wraith, P.K. et al. (1983) The ventilatory effects of doxapram in normal man. Clin Sci 65, 65-9.
43. Cameron, O.G., Lee, M.A., Curtis, G.C. & McCann, D.S. (2008) Endocrine and physiological changes during "spontaneous" panic attacks. Psychoneuroendocrinology 12, 321-31.
44. Cameron, O.G., Model, J.G. & Hariharan, M. (1990) Caffeine and human cerebral blood flow: a positron emission tomography study. Life Sciences 47, 1141-6.
45. Cameron, O.G., Zubieta, J.K., Grunhaus, L. & Minoshima, S. (2000) Effect of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom Med 62, 549-59.
46. Carr, D.B., Sheehan, D.V., Surman, O.S. et al. (1986) Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143, 483-94.
47. Cavallini, M.C., Perna, G., Caldirola, D. & Bellodi, L. (1999) A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge. Biol Psychiatry 46, 815-20.
48. Charney, D.S., Breier, A., Jatlow, P.I. & Heninger, G.R. (1986) Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology 88, 133-40.
49. Charney, D.S. & Bremner, J.D. (1999) The neurobiological basis of anxiety disorders. In: The Neurobiology of Mental Illness (D.S. Charney, E.J. Nestler & B.S. Bunney (eds), pp. 494-517). Oxford University Press, New York.
50. Charney, D.S., Galloway, M.P. & Heninger, G.R. (1984a) The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans. Life Sciences 35, 135-44.
51. Charney, D.S., Goodman, W.K., Price, L.H., Woods, S.W., Rasmussen, S.A. & Heninger, G.R. (1988) Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 45, 177-85.
52. Charney, D.S. & Heninger, G.R. (1985a) Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 42, 458-67.
53. Charney, D.S. & Heninger, G.R. (1985b) Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term imipramine treatment. Arch Gen Psychiatry 42, 473-81.
54. Charney, D.S. & Heninger, G.R. (1986) Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch Gen Psychiatry 43, 1059-65.
55. Charney, D.S., Heninger, G.R. & Breier, A. (1984b) Noradrenergic function in panic anxiety. Arch Gen Psychiatry 41, 751-63.
56. Charney, D.S., Heninger, G.R. & Jatlow, P.I. (1985) Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42, 233-43.
57. Charney, D.S., Heninger, G.R. & Redmond, D.E., Jr (1983) Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sciences 33, 19-29.
58. Charney, D.S., Woods, S.W., Goodman, W.K. & Heninger, G.R. (1987a) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144, 1030-6.
59. Charney, D.S., Woods, S.W., Goodman, W.K. & Heninger, G.R. (1987b) Serotonin function in anxiety II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92, 14-24.
60. Charney, D.S., Woods, S.W. & Heninger, G.R. (1989) Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 27, 173-82.
61. Charney, D.W., Woods, S.W., Keystal, J.H., Nagy, L.M. & Heninger, G.R. (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86, 273-82.
62. Charney, D.S., Woods, S.W., Nagy, L.M., Southwick, S.M., Krystal, J.H. & Heninger, G.R. (1990) Noradrenergic function in panic disorder. J Clin Psychiatry 51(12) (Suppl. A), 5-11.
63. Cohen, M.E. & White, P.D. (1951) Life situations, emotions, and neurocirculatory asthenia (anxiety, neurosis, neurasthenia, effort syndrome). Proc Assoc Res Nerv Ment Dis 29, 832-69.
64. Coplan, J.D., Goetz, G., Klein, D.F. et al. (1998) Plasma cortisol concentrations preceding lactate-induced panic. Arch Gen Psychiatry 55, 130-6.
65. Coplan, J.D., Gorman, J.M. & Klein, D.F. (1992b) Serotonin related functions in panic anxiety: a critical overview. Neuropsychopharmacology 6(3), 189-200.
66. Coplan, J.D. & Klein, D.F. (1996) Pharmacological probes in panic disorder. In: Advances in the Neurobiology of Anxiety Disorders (H.G. Westenberg, J.A. Den Boer & D.L. Murphy (eds), pp. 173-96). John Wiley & Sons, New York.
67. Coplan, J.D., Liebowitz, R., Gorman, J.M. et al. (1992a) Noradrenergic function in panic disorder effects of intravenous clonidine pretreatment on lactate induced panic. Biol Psychiatry 31, 135-46.
68. Coryell, W. & Arndt, S. (1999) The 35% CO2 inhalation procedure: test-retest reliability. Biol Psychiatry 45, 923-7.
69. Coupland, N.J., Bell, C., Potokar, J., Dorkins, E. & Nutt, D.J. (2000) Flumazenil challenge in social phobia. Depress Anxieity 11, 27-30.
70. Coupland, N.J., Lillywhite, A., Bell, C., Potokar, J. & Nutt, D.J. (1997) A pilot study of the effects of flumazenil in post-traumatic stress disorder. Biol Psychiatry 41, 988-90.
71. Cowley, D.S. & Arana, G.W. (1990) The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 47, 277-84.
72. Cowley, D.S., Dager, S.R. & Dunner, D.L. (1986) Lactate-induced panic in primary affective disorder. Am J Psychiatry 143, 646-7.
73. Cowley, D.S., Dager, S.R. & Dunner, D.L. (1987) Lactate infusions in major depression without panic attacks. J Psychiatric Res 21, 234-8.
74. Cowley, D.S., Dager, S.R., McClellan, J., Roy-Byrne, P.P. & Dunner, D.L. (1988) Response to lactate infusion in generalized anxiety disorder. Biol Psychiatry 24, 409-14.
75. Cowley, D.S., Dager, S.R., Roy-Byrne, P.P., Avery, D.H. & Dunner, D.L. (1991) Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry 30, 49-56.
76. Cowley, D.S. & Dunner, D.L. (1988) Response to sodium lactate in panic disorder: relationship to presenting clinical variables. Psychiatry Res 25, 253-59.
77. Dager, S.R., Friedman, S.D., Heide, A. et al. (1999) Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch Gen Psychiatry 56, 70-7.
78. Dager, S.R., Rainey, J.M., Kenny, M.A., Artru, A.A., Metzger, G.D. & Bowden, D.M. (1990) Central nervous system effects of lactate infusion in primates. Biol Psychiatry 27, 193-204.
79. Davis, L.L., Clark, D.M., Kramer, G.L., Moeller, F.G. & Petty, F. (1999) D-fenfluramine challenge in post-traumatic stress disorder. Biol Psychiatry 45, 928-30.
80. De Leeuw, A.S., den Boer, J.A., Slaap, B.R. et al. (1996) Pentagastrin has panic inducing properties in obsessive-compulsive disorder. Psychopharmacology 236, 339-44.
81. De Montigny, C. (1989) Cholecystokinin induces panic like attacks in healthy volunteers. Arch Gen Psychiatry 465, 511-17.
82. Deakin, J.F.W. & Graeff, F.G. (1991) t-HT and mechanisms of defence. J Psychopharmacol 5, 305-15.
83. Den Boer, J.A. & Westenberg, H.G. (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder, a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3, 59-74.
84. Den Boer, J.A., Westenberg, H.G., Klompmakers, A.A. & van Lint, L.E.M. (1989) Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry 26, 612-22.
85. Dépôt. M., Caillé, G., Mukherjee, J., Katzman, M.A., Cadieux, A. & Bradwejn, J. (1998) Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 20, 177-87.
86. Dorow, R., Horowski, R., Paschelke, G., Amin, M. & Baestrup, C. (1983) Severe anxiety induced by FG 7142, a α-carboline ligand for benzodiazepine receptors. Lancet ii, 98-9.
87. Drevets, W.C., Videen, T.Q., MacLeod, A.K., Haller, J.W. & Raichle, M.E. (1992) PET images of blood flow changes during anxiety: correction [letter]. Science 256 (5064), 1696.
88. Erzegovesi, S., Martucci, L., Henin, M. & Bellodi, L. (2001) Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24, 31-6.
89. Facchinetti, F., Romano, G., Fava, M. & Genazzani, A.R. (2004) Lactate infusion induces panic attacks in patients with premenstrual syndrome. Psychosom Med 54, 288-96.
90. George, D.T., Brewerton, T.D. & Jimerson, D.C. (1987) Comparison of lactate-induced anxiety in bulimic patients and healthy controls. Psychiatry Res 21 (3), 213-20.
91. George, D.T., Hibbeln, J.R., Ragan, P.W. et al. (2000) Lactate-induced rage and panic in a select group of subjects who perpetrate acts of domestic violence. Biol Psychiatry 47, 804-12.
92. George, D.T., Lindquist, T., Nutt, D.J. et al. (1995) Effect of chloride or glucose on the incidence of lactate-induced panic attacks. Am J Psychiatry 152 (5), 692-7.
93. Germine, M., Goddard, A.W., Sholomskas, D.E. et al. (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54, 115-33.
94. Germine, M., Goddard, A.W., Woods, S.W., Charney, D.S. & Heninger, G.R. (1992) Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 32, 457-61.
95. Gijsman, H.J., van Greven, J.M.A., Tieleman, M.C. et al. (1998) Pharmacokinetic and pharmacodynamic profile of oral and intravenous metachlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 18, 289-95.
96. Goddard, A.W., Sholomskas, D.E., Walton, K.E. et al. (1994) Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36, 775-7.
97. Goddard, A.W., Woods, S.W., Sholomskas, D.E., Goodman, W.K., Charney, D.S. & Heninger, G.R. (1993) Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 48, 119-33.
98. Goetz, R.R., Klein, D.F. & Gorman, J.M. (1996) Symptoms essential to the experience of sodium lactate-induced panic. Neuropsychopharmacology 14, 355-66.
99. Goetz, R.R., Klein, D.F., Gully, R. et al. (1993) Panic attacks during placebo procedures in the laboratory. Physiological and symptomatology. Arch Gen Psychiatry 50, 280-85.
100. Goodman, W.K., McDougle, C.J., Price, L.H. et al. (1995) m-Chlorophenylpiperazine in patients obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 38, 138-49.
101. Gorman, J.M., Askanazi, J., Liebowitz, M.R. et al. (1984) Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 141, 857-61.
102. Gorman, J.M., Battista, D., Goetz, R.R. et al. (1989) A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Arch Gen Psychiatry 46, 145-50.
103. Gorman, J.M., Charney, D.S., Fyer, M.R., Liebowitz, M.R. & Klein, D.F. (1987) Pharmacological provocation of panic attacks. In: Psychopharmacology: The Third Generation of Progress (H.Y. Meltzer (ed.), pp. 985-93). Raven Press, New York.
104. Gorman, J.M., Fyer, M.R., Goetz, R. et al. (1988b) Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 45, 31-9.
105. Gorman, J.M., Goetz, R.R., Dillon, D. et al. (1990a) Sodium D-lactate infusion in panic disorder patients. Neuropsychopharmacology 3, 181-9.
106. Gorman, J.M., Goetz, R.R., Uy, J. et al. (1988a) Hyperventilation occurs during lactate-induced panic. J Anxiety Disord 2, 193-202.
107. Gorman, J.M., Kent, J.M., Sullivan, G.M. & Coplan, J.D. (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157, 493-505.
108. Gorman, J.M., Levy, G.F., Liebowitz, M.R. et al. (1983) Effect of acute β-adrenergic blockade on lactate-induced panic. Arch Gen Psychiatry 40, 1079-82.
109. Gorman, J.M., Liebowitz, M.R., Fyer, A.J. et al. (1985) Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry 142, 864-6.
110. Gorman, J.M., Papp, L.A., Martinez, J. et al. (1990b) Highdose carbon dioxide challenge test in anxiety disorder patients. Biol Psychiatry 28, 743-57.
111. Griez, E. & van den Hout, M.A. (1986) CO2 inhalation in the treatment of panic attacks. Behav Res Ther 24, 145-50.
112. Gunnarsson, T., Mahoney, C., Shlik, J., Bradwejn, J. & Knott, V. (2000) Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers. Int J Psychopharmacol 3 (Suppl. 1), S277.
113. Gurguis, G.N.M. & Uhde, T.W. (1990) Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 15, 217-24.
114. Gurguis, G.N.M., Vitton, B.J. & Uhde, T.W. (1997) Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 71, 27-39.
115. Guthrie, S.K., Grunhaus, L., Pande, A.C. & Hariharan, M. (2005) Noradrenergic response to intravenous yohimbine in patients with depression and comorbidity of depression and panic. Biol Psychiatry 34, 558-61.
116. Guttmacher, L.B., Murphy, D.L. & Insel, T.R. (1983) Pharmacological models of anxiety. Compr Psychiatry 24, 312-26.
117. Harrington, P.J., Schmidt, N.B. & Telch, M.J. (1996) Prospective evaluation of panic potentiation following 35% CO2 challenge in nonclinical subjects. Am J Psychiatry 153, 823-5.
118. Heninger, G.R., Charney, D.S. & Prince, L.H. (1988) α2-Adrenergic receptor sensitivity in depression. Arch Gen Psychiatry 45, 718-26.
119. Hetem, L.A.B., de Souza, C.J., Guimaraes, F.S., Zuardi, A.W. & Graeff, F.G. (1996) Effect of d-fenfluramine on human experimental anxiety. Psychopharmacology 127, 276-82.
120. Hollander, E., DeCaria, C., Gully, R. et al. (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 36, 1-17.
121. Hollander, E., Liebowitz, M.R., Cohen, B. et al. (1989) Prolactin and sodium lactate-induced panic. Psychiatry Res 28, 181-91.
122. Hollander, E., Liebowitz, M.R., DeCaria, C. & Klein, D.F. (1990) Fenfluramine, cortisol, and anxiety. Psychiatry Res 31, 211-13.
123. Hollander, E., Liebowitz, M.R., Gorman, J.M., Cohen, B., Fryer, A. & Klein, D.F. (1989) Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 46, 135-140.
124. Javanmard, M., Shlik, J., Kennedy, S.H., Vaccarino, F.J., Houle, S. & Bradwejn, J. (1999) Neuroanatomic correlates of CCK-4 induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 45, 872-82.
125. Jensen, C.F., Keller, T.W., Peskind, E.R. et al. (1997) Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with post-traumatic stress disorder. Am J Psychiatry 152, 266-8.
126. Jensen, C.F., Peskind, E.R., Veith, R.C. et al. (1991) Hypertonic saline infusion induces panic in patients with panic disorder. Biol Psychiatry 30, 628-30.
127. Kahn, R.S., Asnis, G.M., Wetzler, S. & van Pragg, H.M. (2009) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96, 360-4.
128. Kahn, R.S. & Wetzler, S. (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30, 1139-66.
129. Keck, P.E., Jr, Taylor, V.E., Tugrul, K.C., McElroy, S.L. & Bennett, J.A. (1993) Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33, 542-6.
130. Kellner, M., Herzog, L., Yassouridis, A., Holsboer, F. & Wiedermann, K. (1995) Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry 152, 1365-7.
131. Kellner, M., Knaudt, K., Jahn, H., Holsboer, F. & Wiedemann, K. (1998) Atrial naturetic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J Psychiatric Res 32, 37-48.
132. Kellner, M., Wiedemann, K., Yassouridis, A. et al. (2000) Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with post-traumatic stress disorder. Biol Psychiatry 41, 107-11.
133. Kellner, M., Yassouridis, A. & Wiedemann, J.H. (1997) Influence of clonidine on psychopathological, endocrine and repiratory effects of cholecystokinin-tetrapeptide in patients with panic disorder. Psychopharmacology 133, 55-61.
134. Kelly, D., Mitchell-Heggs, N. & Sherman, D. (1971) Anxiety and the effects of sodium lactate assessed clinically and physiologically. Br J Psychiatry 119, 129-41.
135. Kennedy, J.L., Bradwejn, J., Koszycki, D. et al. (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4, 284-5.
136. Kent, J.M., Papp, L.A., Martinez, J.M. et al. (2001) Specificity of panic response to CO2 inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am J Psychiatry 158, 58-67.
137. Khanna, S., John, J.P. & Lakshmi Reddy, P. (2001) Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinolgy 26, 209-23.
138. Klaassen, T., Ho Pian, K.L., Westenberg, H.G., den Boer, J.A. & van Praag, H.M. (1998) Serotonin syndrome after challenge with the 5-HT agonist metachlorophenylpiperazine. Psychiatry Res 79, 207-12.
139. Klein, D. (1993) False suffocation alarms, spontaneous panics, and related conditions. Arch Gen Psychiatry 50, 306-17.
140. Klein, E., Zohar, J., Geraci, M.F., Murphy, D.L. & Uhde, T.W. (1991) Anxiogenic effect of mCCP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 30, 973-84.
141. Koszycki, D. (1995) Psychological factors and response to cholecystokinin. In: Cholecystokinin and Anxiety: From Neuron to Behavior (J. Bradwejn & E. Vasar (eds), pp. 87-99). R.G. Landes Co., Austin, TX.
142. Koszycki, D. & Bradwejn, J. (2002) Anxiety sensitivity does not predict fearful responding to 35% carbon dioxide in patients with panic disorder. Psychiatry Res 101, 137-43.
143. Koszycki, D., Zacharko, R.M., Le Melledo, J.-M. & Bradwejn, J. (1998) Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 8, 1-7.
144. Koszycki, D., Zarcharko, R.M., Le Mellédo, J.-M., Young, S.N. & Bradwejn, J. (1996) Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40, 648-55.
145. Kushner, M.G., Mackenzie, T.B., Fiszdon, J. et al. (1996) The effects of alcohol consumption on laboratory-induced panic and state anxiety. Arch Gen Psychiatry 53, 264-70.
146. Le Melledo, J.-M., Bradwejn, J., Koszycki, D., Bichet, D.G. & Bellavance, F. (1998) The role of the β-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry 44, 364-6.
147. Le Mellédo, J.-M., Merani, S., Koszycki, D. et al. (1999) Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 20(1), 81-91.
148. Le Mellédo, J.-M., Van Driel, M., Coupland, N.J. et al. (2000) Response to flumazenil in women with premenstrual dysphoric disorder. Am J Psychiatry 157, 821-3.
149. Lee, Y.-J., Curtis, G.C., Weg, J.G. et al. (1993) Panic attacks induced by doxapram. Biol Psychol 33, 295-7.
150. Lesch, K.P., Wiesmann, M., Hoh, A. et al. (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106, 111-17.
151. Levin, A.P., Doran, A.R., Liebowitz, M.R. et al. (1987) Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21 (1), 23-32.
152. Liebowitz, M.R., Copland, J.D., Martinez, J. et al. (1995) Effects of intravenous diazepam pretreatment of lactate-induced panic. Psychiatry Res 58, 127-38.
153. Liebowitz, M.R., Fyer, A.J., Gorman, J.M. et al. (1984) Lactate provocation of panic attacks. I. Clinical and behavioral correlates. Arch Gen Psychiatry 41, 764-70.
154. Liebowitz, M.R., Fyer, A.J., Gorman, J.M. et al. (1985a) Specificity of lactate infusions in social phobia versus panic disorder. Am J Psychiatry 142, 947-50.
155. Liebowitz, M.R., Gorman, J.M., Fyer, A.J. et al. (1985b) Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42, 709-19.
156. Liebowitz, M.R., Gorman, J.M., Fyer, A.J., Dillon, D., Levitt, M. & Klein, D.F. (1986) Possible mechanisms for lactate's induction of panic. Am J Psychiatry 143, 495-502.
157. Lindy, D.C., Walsh, B.T., Gorman, J.M. et al. (1988) Lactate infusions in patients with bulimia. Psychiatry Res 26(3), 287-92.
158. Lines, C., Challenor, J. & Traub, M. (1995) Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonists L-3650260. Brit J Clin Pharmacol 39, 235-42.
159. Lovallo, W.R., Al'absi, M., Blick, K. et al. (1996) Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav 55, 365-9.
160. Lucas, P.B., Pickar, D., Kelsoe, J., Rapaport, M., Pato, C. & Hommer, D. (1990) Effects of acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28, 35-40.
161. Lucey, J.V., O'Keane, V., Butcher, G., Clare, A.W. & Dinan, T.G. (1992) Cortisol and prolactin responses to d-fenfluramine in nondepressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. Br J Psychiatry 161, 517-21.
162. Malizia, A.L., Cunningham, V.J., Bell, C.J., Liddle, P.F., Jones, T. & Nutt, D.J. (1998) Decreased brain GABA-A-benzodiazepine receptor binding in panic disorder: Preliminary results from a quantitative PET study. Arch Gen Psychiatry 55, 715-20.
163. Mathew, R.J. & Wilson, W.H. (1988) Cerebral blood flow changes induced by CO2 in anxiety. Psychiatry Res 23, 285-94.
164. Matilla, M., Seppala, T. & Matilla, M.J. (1988) Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int J Clin Psychopharmacol 3 (3), 215-29.
165. McCann, U.D., Morgan, C.M., Geraci, M. et al. (1997) Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 17, 360-9.
166. McCann. U.D., Eligulashvili, V. & Ricaurte, G.A. (1998) Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine. Prog Neuropsychopharmacology Biol Psychiatry 22, 1087-102.
167. Miller, H.E.J., Deakin, J.F.W. & Anderson, I.M. (2000) Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry 176, 182-8.
168. Mortimore, C. & Anderson, I.M. (2000) d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacology 149, 251-8.
169. Murphy, D.L., Aulakh, C., Mazzola-Pomietto, P. & Briggs, N.C. (1996) Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Behav Brain Res 73, 209-14.
170. Nardi, A.E., Valenca, A.M., Nascimento, I., Mezzasalma, M.A. & Zin, W.A. (2000) Double-blind acute clonazepam versus placebo in carbon dioxide-induced panic attacks. Psychiatry Res 94(2), 179-84.
171. Nehlig, A., Daval, J.-L. & Debry, G. (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research Reviews 17, 139-70.
172. Nesse, R.M., Cameron, O.G., Curtis, G.C., McCann, D.S. & Huber-Smith, M.J. (1984) Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41, 771-6.
173. Nickell, P.V. & Uhde, T.W. (1995) Dose-response of intravenous caffeine in normal volunteers. Anxiety 1, 161-8.
174. Noble, F., Wank, S.A., Crawley, J.N. et al. (2000) International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacological Reviews 51, 745-81.
175. Norman, T.R., Apostolopoulos, M., Burrows, G.D. & Judd, F.K. (1994) Neuroendocrine responses to single doses of buspirone in obsessive-compulsive disorder. Int Clin Psychopharmacol 9, 89-94.
176. Nutt, D.J., Glue, P., Lawson, C. & Wilson, S. (1990) Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 47, 917-25.
177. Nutt, D.J. & Lawson, C. (1992) Panic attacks. a neurochemical overview of the models and mechanisms. Br J Psychiatry 161, 517-21.
178. Orlikov, A. & Ryzov, I. (1991) Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot project. Biol Psychiatry 29, 391-6.
179. Papp, L.A., Goetz, R., Cole, R. et al. (1989) Hypersensitivity to carbon dioxide in panic disorder. Am J Psychiatry 146, 779-81.
180. Papp, L.A., Klein, D.F., Martinez, J. et al. (1993) Diagnostic and substance specificity of carbon-dioxide-induced panic. Am J Psychiatry 150, 250-7.
181. Papp, L.A., Martinez, J.M., Klein, D.F. et al. (1997) Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry 154, 1557-65.
182. Perna, G., Bertani, B., Arancio, C., Ronchi, P. & Bellodi, L. (1995b) Laboratory response of patients with panic obsessive-compulsive disorders to 35% CO2 challenges. Am J Psychiatry 152, 85-9.
183. Perna, G., Bertani, B., Cocchi, S., Bertani, A. & Gasperini, M. (1995c) 35% CO2 challenge in panic and mood disorders. J Affect Disord 33, 189-94.
184. Perna, G., Bertani, A., Gabriele, A. & Bellodi, L. (1997) Modification of 35% carbon dioxide hypersensitivity across 1 week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 17, 173-8.
185. Perna, G., Bussi, R., Allevi, L. & Bellodi, L. (1999a) Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry 60, 379-84.
186. Perna, G., Cocchi, S., Allevi, L., Bussi, R. & Bellodi, L. (1999b) A long-term prospective evaluation of first-degree relatives of panic patients who underwent 35% CO2 challenge. Biol Psychiatry 45, 365-7.
187. Perna, G., Cocchi, S., Bertani, A., Arancio, C. & Bellodi, L. (1994) Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study. J Clin Psychopharmacol 14, 414-18.
188. Perna, G., Cocchi, S., Bertani, A., Arancio, C. & Bellodi, L. (1995d) Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry 152, 623-5.
189. Perna, G., Gabriele, A., Caldirola, D. & Bellodi, L. (1995a) Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res 57, 267-73.
190. Peskind, E.R., Jensen, C.F., Pascualy, M. et al. (1998) Sodium lactate and hypertonic sodium choloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 44, 1007-16.
191. Pine, D.S., Coplan, J.D., Papp, L.A. et al. (1998) Ventilatory physiology of children and adolescents with anxiety disorders. Arch Gen Psychiatry 55, 123-9.
192. Pine, D.S., Klein, R.G., Coplan, J.D. et al. (2000) Differential carbon dioxide sensitivity in childhood anxiety disorders and nonill comparison group. Arch Gen Psychiatry 57, 960-7.
193. Pine, D.S., Weese-Mayer, D.E., Silvestri, J.M., Davies, M., Whitaker, A.H. & Klein, D.F. (1994) Anxiety and the congenital central hypoventilation syndrome. Am J Psychiatry 151, 864-70.
194. Pitts, F.N. Jr & McClure, J.N. Jr (1967) Lactate metabolism in anxiety neurosis. N Engl J Med 277, 1329-36.
195. Pohl, R., Balon, R. & Lycaki, H. (1994) Lactate-induced anxiety after imipramine and diazepam treatment. Anxiety 1(2), 54-63.
196. Pohl, R., Pandey, G.N., Yeragani, V.K., Balon, R., Davis, J.M. & Berchou, R. (1993) β-Receptor responsiveness after desipramine treatment. Psychopharmacology 110, 37-44.
197. Pohl, R., Yeragani, V.K. & Balon, R. (1990) Effects of isoproterenol in panic disorder patients after antidepressant treatment. Biol Psychiatry 28, 203-14.
198. Pohl, R., Yeragani, V.K., Balon, R. et al. (1988a) Isoproterenol-induced panic attacks. Biol Psychiatry 24, 891-902.
199. Pohl, R., Yeragani, V.K., Balon, R. & Lycaki, H. (1989) Lactate and isoproterenol infusions in bulimic patients. Neuropsychobiology 22, 225-30.
200. Pohl, R., Yergani, V.K., Balon, R. & Lycaki, H. (1988b) The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49, 100-4.
201. Pols, H.J., Hauzer, R.C., Meijer, J.A., Verburg, K. & Griez, E.J. (1996a) Fluvoxamine attenuates panic induced by 35% CO2 challenge. J Clin Psychiatry 57, 539-42.
202. Pols, H., Verburg, K., Hauzer, R., Meijer, J. & Griez, E. (1996b) Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Biol Psychiatry 40, 913-17.
203. Pols, H., Zandbergen, J., de Loof, C. et al. (1991) Attenuation of carbon dioxide-induced panic after clonazepman treatment. Acta Psychiatr Scand 84, 885-6.
204. Pyke, R.E. & Greenberg, H.S. (1986) Norepinephrine challenges in panic patients. J Clin Psychopharmacol 6, 279-85.
205. Rainey, J.M., Aleem, A., Ortiz, A., Yeragani, V., Pohl, R. & Berchou, R. (1987) A laboratory procedure for the induction of flashbacks. Am J Psychiatry 144, 1317-19.
206. Rainey, J.M., Frohman, C.E., Freedman, R.R., Pohl, R.B., Ettedgui, E. & Williams, M. (1984a) Specificity of lactate infusion as a model of anxiety. Psychopharmacol Bull 20, 45-57.
207. Rainey, J.M., Pohl, R.B., Williams, M., Knitter, E., Freedman, R.R. & Ettedgui, E. (1984c) A comparison of lactate and isoproterenol anxiety states. Psychopathology 17 (Suppl. 1), 74-82.
208. Rainey, M., Jr, Ettedgui, E., Pohl, B. et al. (1984b) The β-receptor: isoproterenol anxiety states. Psychopathology 17 (Suppl. 3), 40-51.
209. Rasmussen, S.A., Goodman, W.K., Woods, S.W., Henninger, G.R. & Charney, D.S. (1987) Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology 93, 308-13.
210. Redmond, D.E. (1977) Alterations in the function of the nucleus locus ceruleus: a possible model for studies in anxiety. In: Animal Models in Psychiatry and Neurology (I. Hanin & E. Usdin (eds), 293-304). Pergamon Press, New York.
211. Reiman, E.M., Raichle, M.E., Robins, E. et al. (1986) The application of positron emission tomography to the study of panic disorder. Am J Psychiatry 143, 469-77.
212. Reiman, E.M., Raichle, M.E., Robins, E. et al. (1989) Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 46, 493-500.
213. Reschke, A.H., Mannuzza, S., Chapman, T.F. et al. (1995) Sodium lactate response and familial risk for panic disorder. Am J Psychiatry 152, 277-9.
214. Rifkin, A., Klein, D., Dillon, D. & Levitt, M. (1981) Blockade by imipramine or desipramine of panic induced by sodium lactate. Am J Psychiatry 138, 676-7.
215. Rowland, B.E. & Carlton, J. (1986) Neurobiology of an anorectic drug: fenfluramine. Progress in Neurobiology 27, 13-62.
216. Roy-Byrne, P.P., Cowley, D.S., Greenblatt, D.J., Shader, R.I. & Hommer, D. (1990) Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47, 534-8.
217. Salkovskis, P.M. & Clark, D.M. (1990) Affective responses to hyperventilation: a test of the cognitive model of panic. Behav Res Ther 28, 51-61.
218. Sallee, F.R., Sethuraman, G., Sine, L. & Liu, H. (2000) Yohimbine challenge in children with anxiety disorders. Am J Psychiatry 157, 1236-42.
219. Sandberg, D., Endicott, J., Harrison, W., Nee, J. & Gorman, J. (1993) Sodium lactate infusion in late luteal phase dysphoric disorder. Psychiatry Res 46, 79-88.
220. Sanderson, W.C., Wetzler, S. & Asnis, G.M. (1994) Alprazolam blockade in CO2-provoked panic in patients with panic disorder. Am J Psychiatry 151, 1220-2.
221. Schmidt, N.B., Telch, M.J. & Jaimez, T.L. (1996) Biological challenge manipulation of Pco2 levels: a test of Klein's (1993) suffocation alarm theory of panic. J Abnorm Psychol 105, 446-54.
222. Schruers, K., Klaassen, T., Pols, H., Overbeek, T., Deutz, N.E.P. & Griez, E. (2000) Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res 93, 179-87.
223. Sevy, S., Brown, S.L., Wetzler, S. et al. (1994) Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res 53, 219-29.
224. Shear, M.K. (1986) Pathophysiology of panic: a review of pharmacologic provocation tests and naturalistic monitoring data. J Clin Psychiatry 4 (Suppl. 6), 18-26.
225. Shear, M.K., Fyer, A.J., Ball, G. et al. (1991) Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy. Am J Psychiatry 148, 795-97.
226. Shekhar, A. & Keim, S.R. (1997) The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J Neurosci 17, 9726-35.
227. Shlik, J., Aluoja, A., Vasar, V., Vasar, E., Podar, T. & Bradwejn, J. (1997a) Effects of citalopram treatment on behavioral, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Revue de psychiatrie et du neuroscience 22, 332-40.
228. Shlik, J., Vasar, V., Aluoja, A. et al. (1997b) The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry 42, 206-12.
229. Shlik, J., Vasar, E. & Vasar, V. (2000) Clonidine does not block CCK-4 induced panic in healthy volunteers. Int J Neuropsychopharmacol 3 (Suppl. 1), S290.
230. Sinha, S.S., Coplan, J.D., Martinez, J.A., Klein, D.F. & Gorman, J.M. (1999) Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 86(2), 93-8.
231. Southwick, S.M., Krystal, J.H., Bremner, J.D. et al. (1997) Noradrenergic and serotonergic function in post-traumatic stress disorder. Arch Gen Psychiatry 54, 749-58.
232. Southwick, S.M., Morgan, C.A., Charney, D.S. & High, J.R. (1999) Yohimbine use in a natural setting: effects on post-traumatic stress disorder. Biol Psychiatry 46, 442-4.
233. Stein, M.B. et al. (1999) Single photon emission computed tomography of the brain with Tc-99m HMPAQ during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin autoreceptor. Prog Neuropsychopharmacological Biol Psychiatry 23, 1079-99.
234. Stein, M.B. & Uhde, T.W. (1989) Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biol Psychiatry 26 (3), 315-20.
235. Ströhle, A., Kellner, M., Holsboer, F. & Wiederman, K. (2002) Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155, 610-12.
236. Ströhle, A., Kellner, M., Holsboer, F. & Wiederman, K. (2000) Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzo-diazepine receptor sensitivity in panic disorder. Biol Psychiatry 45, 321-6.
237. Sullivan, G.M., Coplan, J.D., Kent, J.M. & Gorman, J.M. (1999) The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry 46, 1205-18.
238. Tancer, M.E., Black, B. & Brown, T.M. (1991) Phenomenology and neurobiology of social phobia: comparison with panic disorder. J Clin Psychiatry 52 (Suppl.), 31-40.
239. Tanum, L. & Malt, U.F. (1995) Sodium lactate infusion in fibromyalgia patients. Biol Psychiatry 38, 559-61.
240. Targum, S.D. (1990) Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28, 21-34.
241. Targum, S.D. (1992) Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 17(5), 453-8.
242. Targum, S.D. & Marshall, L.E. (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28, 295-306.
243. Uhde, T.W. (1990) Caffeine provocation on panic: a focus on biological mechanisms. Neurobiology of Panic Disorder. Alan R. Liss, New York, pp. 219-42.
244. Uhde, T.W., Boulenger, J.-P., Jimerson, D.C. & Post, R.M. (1984) Caffeine: relationship to human anxiety, plasma MHPG, and cortisol. Psychopharmacol Bull 20, 426-30.
245. Uhde, T.W., Tancer, M.E., Rubinow, D.R. et al. (1992) Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile to growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6(2), 101-18.
246. Van den Hout, M.A. & Griez, E. (1984) Panic symptoms after inhalation of carbon dioxide. Br J Psychiatry 144, 503-7.
247. Van der Wee, N., Fiselier, J., van Megen, H.G., Van Vliet, I. & Westenberg, H.G. (1999) Behavioral effects of rapid intravenous challenge with meta-chlorophenyl-piperazine (0.1 mg/kg) in patients with panic disorder and controls. Eur Neuropsychopharmacol 9 (Suppl. 5), S308.
248. Van Megen, H.G., Westenberg, H.G., den Boer, J.A., Haigh, J.R. & Traub, M. (1994) Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 114, 449-55.
249. Van Megen, H.G., Westenberg, H.G., den Boer, J.A., Slaap, B. & Scheepmakers, A. (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamiine on CCK-4-induced panic attacks. Psychopharmacology 129, 357-64.
250. Van Vliet, I.M., Slaap, B.R., Westenberg, H.G. & Den Boer, J.A. (1996) Behavioral, neuroendocrine, and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6, 103-110.
251. Veltman, D.J., van Zijderveld, G.A. & van Dyck, R. (1996) Epinephrine infusions in panic disorder: a double-blind placebo-controlled study. J Affect Disord 39, 133-40.
252. Veltman, D.J., van Zijderveld, G.A., van Dyck, R. & Bakker, A. (1998) Predictability, controllability, and fear of symptoms of anxiety in epinephrine-induced panic. Biol Psychiatry 44, 1017-26.
253. Verburg, C., Griez, E. & Meijer, A. (1994) A 35% carbon dioxide challenge in simple phobias. Acta Psychiatr Scand 90, 420-3.
254. Verburg, C., Griez, E., Meijer, J. & Pols, H. (1995) Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiatry 152, 1081-3.
255. Verburg, C., Pols, H., de Leeuw, M. & Griez, E. (1998) Reliability of 35% carbon dioxide panic provocation challenge. Psychiatry Res 78, 207-14.
256. Westenberg, H.G. & den Boer, J.A. (1989) Serotonin function in panic disorder: effect of 1-5-hydroxytryptophan in patients and controls. Psychopharmacology 98, 283-5.
257. Wetzler, S., Asnis, G.M., DeLecuona, J.M. & Kalus, O. (1992) Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 64, 77-82.
258. Woods, S.W., Charney, D.S., Delgado, P.L. & Heninger, G.R. (1990) The effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. J Clin Psychiatry 5, 505-7.
259. Woods, S.W., Charney, D.S., Goodman, W.K. & Heninger, G.R. (1988a) Carbon dioxide-induced anxiety. Arch Gen Psychiatry 45, 43-52.
260. Woods, S.W., Charney, D.S., Loke, J., Goodman, W.K., Redmond, D.E. Jr & Heninger, G.R. (1986) Carbon dioxide sensitivity in panic anxiety. Arch Gen Psychiatry 43, 900-9.
261. Woods, S.W., Charney, D.S., McPherson, C.A., Gradman, A.H. & Heninger, G.R. (1987) Situational panic attacks: behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44, 365-75.
262. Woods, S.W., Charney, D.S., Silver, J.M., Krystal, J.H. & Henninger, G.R. (1991) Behavioral, neuroendocrine, and cardiovascular response to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 36, 115-27.
263. Woods, S.W., Koster, K., Krystal, J.K. et al. (1988b) Yohimbine alters regional cerebral blood flow in panic disorder. Lancet 2, 678.
264. Woods, S.W., Krystal, J.H., D'Amico, C.L., Heninger, G.R. & Charney, D.S. (1988c) A review of behavioral and pharmacologic studies relevant to the application of CO2 as a human subject model of anxiety. Psychopharmacol Bull 24, 149-53.
265. Woods, S.W., Krystal, J.H., Heninger, G.R. & Charney, D.S. (1989) Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sciences 45, 233-42.
266. Yeragani, V.K., Pohl, R., Balon, R., Rainey, J.M., Berchou, R. & Ortiz, A. (1988) Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. Biol Psychiatry 24, 767-74.
267. Yeragani, V.K., Pohl, R., Srinivasan, K., Balon, R., Ramesh, C. & Berchou, R. (1995) Effects of isoproterenol infusions on heart rate variability in patients with panic disorder. Psychiatry Res 56, 289-93.
268. van Zijderveld, G.A., TenVoorde, B.J., Veltman, D.J. et al. (1993) Cardiovascular, respiratory, and panic reactions to epinephrine in panic disorder patients. Biol Psychiatry 41, 249-51.
269. van Zijderveld, G.A., van Doornen, L.J.P., van Faassen, I. et al. (1992) The psychophysiological effects of adrenaline infusions as a function of trait anxiety and aerobic fitness. Anxiety Res 4, 257-74.
270. van Zijderveld, G.A., Veltman, D.J., van Dyck, R. & van Doornen, L.J. (1999) Epinephrine-induced panic attacks and hyperventilation. J Psychiatr Res 33 (1), 73-8.
271. Zohar, J., Mueller, E.A., Insel, T.R., Zohar-Kadouch, R.C. & Murphy, D.L. (1987) Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 44, 946-51.
272. Zohar, J., Thomas, T.R., Zohar-Kadouch, R.C., Hill, J.R. & Murphy, D.L. (1988) Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 45, 167-72.